NO960956L - Rekombinante IL4-antistoffer anvendelige ved behandling av IL4-betingede forstyrrelser - Google Patents

Rekombinante IL4-antistoffer anvendelige ved behandling av IL4-betingede forstyrrelser

Info

Publication number
NO960956L
NO960956L NO960956A NO960956A NO960956L NO 960956 L NO960956 L NO 960956L NO 960956 A NO960956 A NO 960956A NO 960956 A NO960956 A NO 960956A NO 960956 L NO960956 L NO 960956L
Authority
NO
Norway
Prior art keywords
recombinant
treatment
related disorders
antibodies useful
antibodies
Prior art date
Application number
NO960956A
Other languages
English (en)
Norwegian (no)
Other versions
NO960956D0 (no
Inventor
Stephen Dudley Holmes
Mitchell Stuart Gross
Daniel R Sylvester
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of NO960956D0 publication Critical patent/NO960956D0/no
Publication of NO960956L publication Critical patent/NO960956L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO960956A 1993-09-07 1996-03-07 Rekombinante IL4-antistoffer anvendelige ved behandling av IL4-betingede forstyrrelser NO960956L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11736693A 1993-09-07 1993-09-07
US13678393A 1993-10-14 1993-10-14
PCT/US1994/010308 WO1995007301A1 (en) 1993-09-07 1994-09-07 Recombinant il4 antibodies useful in treatment of il4 mediated disorders

Publications (2)

Publication Number Publication Date
NO960956D0 NO960956D0 (no) 1996-03-07
NO960956L true NO960956L (no) 1996-05-06

Family

ID=26815208

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960956A NO960956L (no) 1993-09-07 1996-03-07 Rekombinante IL4-antistoffer anvendelige ved behandling av IL4-betingede forstyrrelser

Country Status (21)

Country Link
EP (1) EP0730609B1 (uk)
JP (4) JPH09502708A (uk)
KR (1) KR100362340B1 (uk)
CN (2) CN1105728C (uk)
AP (1) AP583A (uk)
AT (1) ATE286510T1 (uk)
AU (1) AU695726B2 (uk)
BG (1) BG63549B1 (uk)
BR (1) BR9407575A (uk)
CA (1) CA2171336C (uk)
CZ (1) CZ295928B6 (uk)
DE (1) DE69434223T2 (uk)
ES (1) ES2236693T3 (uk)
FI (1) FI119733B (uk)
HU (1) HU222041B1 (uk)
NO (1) NO960956L (uk)
NZ (1) NZ274338A (uk)
PL (1) PL180125B1 (uk)
SK (1) SK285556B6 (uk)
UA (1) UA48940C2 (uk)
WO (1) WO1995007301A1 (uk)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
WO2005080432A2 (en) 2004-02-19 2005-09-01 Genentech, Inc. Cdr-repaired antibodies
AR050044A1 (es) * 2004-08-03 2006-09-20 Novartis Ag Anticuerpo especifico de il-4
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2007147600A2 (en) 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP4971872B2 (ja) 2007-05-23 2012-07-11 株式会社トプコン 眼底観察装置及びそれを制御するプログラム
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5324839B2 (ja) 2008-06-19 2013-10-23 株式会社トプコン 光画像計測装置
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102294024B (zh) * 2011-01-17 2013-03-13 广东现代农业集团研究院有限公司 一种多肽疫苗及其制备方法
CN107614762B (zh) * 2015-02-24 2022-08-05 台湾地区“中央研究院” 一种由噬菌体表达的单链变异片段抗体库
MD4172199T2 (ro) * 2020-06-26 2025-09-30 Bioarctic Ab Anticorpi care leagă protofibrila de alfa-sinucleină
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
CN114920845A (zh) * 2020-12-31 2022-08-19 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用
AU2023228391A1 (en) * 2022-03-03 2024-09-19 Pfizer Inc. Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用
WO2025076048A1 (en) * 2023-10-02 2025-04-10 Fred Hutchinson Cancer Center Anti-cd90 antibodies, binding fragments, and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
JP2646007B2 (ja) * 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH07119238B2 (ja) * 1989-12-18 1995-12-20 小野薬品工業株式会社 ヒトインターロイキン―４に対するモノクローナル抗体および該抗体の利用方法
PT96230B (pt) * 1989-12-20 1998-06-30 Schering Corp Processo para a producao de um polipeptideo e anticorpos antagonistas da interleuquina-4 humana
JPH04141095A (ja) * 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
NZ249677A (en) * 1992-02-19 1996-08-27 Schering Corp Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies
JPH06269663A (ja) * 1993-03-17 1994-09-27 Toyobo Co Ltd Ｃｄ４陽性細胞捕集材
EP1200371B1 (en) * 1999-07-30 2006-01-04 Battelle Memorial Institute Glass-ceramic joining material and method of joining

Also Published As

Publication number Publication date
WO1995007301A1 (en) 1995-03-16
CA2171336C (en) 2011-06-21
KR100362340B1 (ko) 2003-02-26
FI961083L (fi) 1996-05-06
JP2009191077A (ja) 2009-08-27
SK33396A3 (en) 1996-10-02
DE69434223T2 (de) 2005-12-22
EP0730609A4 (en) 2000-05-10
JP2006333870A (ja) 2006-12-14
BG63549B1 (bg) 2002-04-30
CZ69896A3 (en) 1996-10-16
PL313491A1 (en) 1996-07-08
JPH09502708A (ja) 1997-03-18
PL180125B1 (pl) 2000-12-29
SK285556B6 (sk) 2007-03-01
HU222041B1 (hu) 2003-04-28
BR9407575A (pt) 1996-07-16
AU7834094A (en) 1995-03-27
NZ274338A (en) 1998-02-26
ES2236693T3 (es) 2005-07-16
AU695726B2 (en) 1998-08-20
CZ295928B6 (cs) 2005-12-14
EP0730609B1 (en) 2005-01-05
CN1105728C (zh) 2003-04-16
CN1473854A (zh) 2004-02-11
CN1133599A (zh) 1996-10-16
BG100480A (bg) 1996-12-31
AP9600782A0 (en) 1996-04-30
EP0730609A1 (en) 1996-09-11
HUT75833A (en) 1997-05-28
NO960956D0 (no) 1996-03-07
DE69434223D1 (de) 2005-02-10
FI961083A0 (fi) 1996-03-07
AP583A (en) 1997-04-14
JP2007045831A (ja) 2007-02-22
HU9600616D0 (en) 1996-05-28
CA2171336A1 (en) 1995-03-16
UA48940C2 (uk) 2002-09-16
FI119733B (fi) 2009-02-27
ATE286510T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
NO960956L (no) Rekombinante IL4-antistoffer anvendelige ved behandling av IL4-betingede forstyrrelser
FI955798A7 (fi) Terapeuttiset vasta-ainefrangmentit
CY2015056I1 (el) Ανασυνδυασμενοι antαγωνιστες της il-5 που ειναι χρησιμοι στη θεραπεια διαταραχων που διαμεσολαβουνται απο την il-5
FI962249A7 (fi) Substituoituja pyratsolyylibentseenisulfonamideja tulehduksen hoitoa varten
ZA946875B (en) Recombinant il4 antibodies useful in treatment of il4 mediated disorders
FI933034A7 (fi) Farmaceutisk produkt behaollare foer tvao avskilda substanser med en blandnings- och doseringsanordning
DE69320362D1 (de) Nicht-wässrige emulgierte oberflächenbehandlungszusammensetzung
FI925530A7 (fi) Rekombinanttisesti tuotetut lipaasit terapeuttiseen käyttöön
FI961630A7 (fi) Terapeuttisia aineita
FI952204A7 (fi) Terapeuttisia aineita
NO965247D0 (no) Anvendelse av kryssbundet hemoglobin ved behandling av subarakuoidalblödning
DE69516229D1 (de) Verbesserungen beim Herstellen von Glascontainern
DE69515413D1 (de) Verbesserungen beim Herstellen von Glascontainern
FI943213A7 (fi) Prosessi valmistaa 3-asyyliestratrieenejä ja asyylibentseenejä
NO962503D0 (no) Anvendelse av penoksyfyllin ved behandling av multippel sklerose
HK1013654A (en) Recombinant il4 antibodies useful in treatment of il4 mediated disorders
KR930021041U (ko) 식기세척기의 상판과 케이스의 결합수단
KR950019391U (ko) 자동차의 가변 흡기장치
KR950008161U (ko) 개인용 찜질사우나
NO944296D0 (no) Diaminer ved behandling av arrhytmi
LV5392A3 (lv) Ziede *evija" apdegumu un brucu arstesanai
KR940023078U (ko) 지압효과를 갖는 라이터
FI1295U1 (fi) En baerande traekonstruktion
SE9203815D0 (sv) Haga cykellaas
KR950011449U (ko) 자동차의 인판넬